Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Monte Rosa Therapeutics, Inc. (GLUE : NSDQ)
 
 • Company Description   
Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

Number of Employees: 93

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.35 Daily Weekly Monthly
20 Day Moving Average: 155,712 shares
Shares Outstanding: 46.67 (millions)
Market Capitalization: $389.68 (millions)
Beta:
52 Week High: $45.56
52 Week Low: $7.22
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -34.51% -26.25%
12 Week -43.08% -37.43%
Year To Date -59.11% -51.11%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
645 SUMMER STREET SUITE 102
-
BOSTON,MA 02210
USA
ph: 617-949-2643
fax: -
ir@monterosatx.com http://www.monterosatx.com
 
 • General Corporate Information   
Officers
Markus Warmuth - Chief Executive Officer; President
Ajim Tamboli - Chief Financial Officer
Alexander Mayweg - Director
Bradley J. Bolzon - Director
Ali Behbahani - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 61225M102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 46.67
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $389.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.23 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.20
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -24.47
12/31/21 - -27.56
09/30/21 - -
ROA
03/31/22 - -23.37
12/31/21 - -26.43
09/30/21 - -
Current Ratio
03/31/22 - 25.65
12/31/21 - 20.96
09/30/21 - 29.08
Quick Ratio
03/31/22 - 25.65
12/31/21 - 20.96
09/30/21 - 29.08
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.98
12/31/21 - 7.47
09/30/21 - 7.96
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©